BDX · Becton, Dickinson and Company

Healthcare NYQ United States bd.com ↗
Val Gro Qua Mom Sta Cap P/S2.15 P/E Fwd P/E13.38 PEG1.11 52W –  RSI Target$195.67 (+10.0%) Beta0.28 Div2.38%
Loading chart…
RSI ()
Pattern Overlays
Loading patterns…
Medical Instruments & Supplies Franklin Lakes, United States 72,000 employees
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company has a strategic collaboration with ChemoGLO for the advancement of hazardous drug contamination testing in health care settings to improve the safety of health care workers. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
Signal
Trend Strength
Price Levels
52-Week Range
52W Low 52W High
Position in Range
RSI (14)
0 · Oversold RSI 45 Overbought · 100
Signal Neutral
EMA Price Levels
Activity & Patterns
Volume Analysis
Momentum Dashboard
Detected Patterns
7Bullish
5Bearish
0Neutral

Key Signals 3

▲ Double Bottom Major reversal 2026-06-05 · $149.68
Two lows ~$141.48 — bullish reversal confirmed
Learn more →
▲ Double Bottom Major reversal 2026-06-26 · $152.55
Two lows ~$141.12 — bullish reversal confirmed
Learn more →
▼ Double Top Major reversal 2026-06-17 · $142.13
Two peaks ~$151.12 — bearish reversal confirmed
Learn more →

Momentum Signals 9

▲ MACD Bullish Crossover 2026-05-08 · $148.38
▲ MACD Bullish Crossover 2026-06-25 · $151.38
▲ MACD Bullish Crossover 2026-07-15 · $154.88
▲ Bull Flag 2026-07-27 · $158.27

View overlays on the price chart via Overview tab → Pattern Overlays.

Next Earnings Nov 05, 2026
Beat Rate 100%
Consensus BUY
Analyst Upside +10.0%
EPS — History & Forecast
Estimate Beat Miss Forecast
Loading…
Revenue — History & Forecast
Revenue Forecast
Loading…
EPS Beat Rate
100% 8/8 quarters
Wall Street Consensus
BUY
7
7
BuyHoldSell
Price Target Range
$195.67 +10.0% upside
Low $170 High $225
Consensus Current price
Wall Street Analyst Ratings
Sort by
Firm Rating Change Action Date
Profitability
Gross Margin 46.94%Last 12 Months
Operating Margin 15.73%Last 12 Months
Return on Equity 6.61%Last 12 Months
Revenue Growth 5.40%Year over Year
Free Cash Flow 4.48BLast 12 Months
Free Cash Flow Yield Last 12 Months
Balance Sheet
Debt / Equity 68.84Most Recent Quarter
Current Ratio 0.86Most Recent Quarter
Cash 709.00MMost Recent Quarter
Total Debt 16.81BMost Recent Quarter
Net Debt Most Recent Quarter
How BDX Makes Its Money
Cash Flow Breakdown
Quarterly Metrics
QuarterRevenueRev YoYGross Profit Op. IncomeNet IncomeNet YoY Gross %Op %Net %
Full Key Statistics
Valuation
Market Cap48.44B
Enterprise Value64.54B
Trailing P/E30.51
Forward P/E13.38
PEG Ratio (5yr)1.11
Price/Sales (ttm)2.15
Price/Book (mrq)1.98
EV/Revenue2.87
EV/EBITDA10.54
Share Statistics
Avg Vol (3m)2.10M
Shares Outstanding272.39M
Float271.66M
% Held by Insiders0.43%
% Held by Institutions99.71%
Short Ratio5.76
Short % of Float4.47%
Profitability
Gross Margin46.94%
Operating Margin (ttm)15.73%
Profit Margin4.19%
Return on Assets (ttm)4.34%
Return on Equity (ttm)6.61%
Income Statement
Revenue (ttm)22.48B
Revenue Growth (yoy)5.40%
Gross Profit (ttm)10.55B
EBITDA6.12B
Net Income (ttm)1.65B
Diluted EPS (ttm)5.83
EPS Growth (yoy)-31.40%
Balance Sheet
Total Cash (mrq)709.00M
Total Debt (mrq)16.81B
Debt / Equity (mrq)68.84
Current Ratio (mrq)0.86
Book Value / Share89.64
Operating CF (ttm)3.34B
Free Cash Flow (ttm)4.48B
Trading & Dividends
Beta (5Y)0.28
50-Day MA171.46
200-Day MA160.22
Fwd Dividend Yield2.38%
Payout Ratio72.49%
Income
Dividend Yield 2.38%Last 12 Months
Annual Rate 4.20Forward
Payout Ratio 72.49%Last 12 Months
Dividend History
Payout Ratio (Last 12 Months): 72.49%
Monthly Dividends
Ownership Breakdown
Institutional 99.71% Insider 0.43%
Short Interest 4.47% of float
Moderate
Institutional 13F Holdings

Famous investors who disclosed a position in BDX in their latest SEC 13F filing.

Loading…
Insider Transactions
Date Insider Role Transaction Shares Price Value